A leading pharmaceutical and biopharmaceutical company has begun an expansion of its Tredegar facility.
PCI Pharma Services, a global outsourcing solutions provider, is looking to enhance its high potent drug manufacturing and development capabilities, including both clinical and commercial supply.
The investment involves an extension to the manufacturing facility that is estimated to be completed by late 2021.
“Pharmaceutical and biopharmaceutical companies are innovating drug treatments today at a rapid pace and in greater volume. As the market continues to grow, we’ve seen an increasing number of clients look to us to provide manufacturing services across the spectrum of dosage forms,” said Richard Yarwood, chief scientific officer, PCI Pharma Services.
“The expansion at Tredegar will double our large-scale manufacturing capacity to ensure that new and existing customers have their development and supply needs met now and in the future.”
Salim Haffar, CEO, PCI Pharma Services, added: “Growing our manufacturing capabilities in Tredegar demonstrates our commitment to manufacturing and providing this service to clients who need a supply chain partner throughout the entire process, from drug development to commercialization.”03:9
.jpg?w=600)
